Clinical Trial Update: A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2a study evaluating DB-1303/BNT323 in HER2-positive advanced solid tumors is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors

Drugs mentioned

• DB-1303/BNT323

Snippet

Sponsor: DualityBio Inc. | Conditions: HER2-positive Advanced Solid Tumor | Phase 1, Phase 2 | Status: RECRUITING